Drug Approvals

Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
It's pretty normal to have profit-taking after such a strong first quarter.
Biotech companies show more energy than the rest of the market Monday.
On an inconsistent day in the markets, some ask if now's the time to buy Valeant.
U.S. stocks saw slow action ahead of the start of a Fed meeting and a big East Coast snow storm Tuesday.
Most of the 10 best stocks of the bull market did it their way.
The firms all have drugs they want the feds to bend the rules to approve.
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Static doesn't work in this industry. Pipelines work.
The Actelion buyout opens the way for other deals.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.